All patients N = 119 (%) | IB CR + PR N = 69 (%) | IB SD N = 35 (%) | IB PD N = 15 (%) | p value | |
---|---|---|---|---|---|
Median age at diagnosis in years (range) | 64 (23–90) | 66 (23–90) | 63 (40–86) | 64 (38–89) | 0.67 |
Median age at ibrutinib therapy in years (range) | 68 (27–91) | 69 (27–90) | 67 (42–86) | 65 (41–91) | 0.74 |
Gender | 0.89 | ||||
Male | 55 (46) | 33 (48) | 15 (43) | 7 (47) | |
Female | 64 (54) | 36 (52) | 20 (57) | 8 (53) | |
BMI | 0.95 | ||||
< 30 | 71 (71) | 43 (72) | 20 (69) | 8 (73) | |
≥ 30 | 29 (29) | 17 (28) | 9 (31) | 3 (27) | |
Missing | 19 | 9 | 6 | 4 | |
ECOG PS at diagnosis | 0.53 | ||||
0 | 46 (46.5) | 25 (42) | 13 (50) | 8 (61) | |
1 | 47 (47.5) | 32 (53) | 11 (42) | 4 (31) | |
≥ 2 | 6 (6) | 3 (5) | 2 (8) | 1 (8) | |
Missing | 20 | 9 | 9 | 2 | |
MZL subtype | 0.97 | ||||
NMZL | 50 (42) | 28 (41) | 17 (49) | 5 (33) | |
SMZL | 29 (24) | 17 (25) | 8 (23) | 4 (27) | |
EMZL | 40 (34) | 24 (34) | 10 (28) | 6 (40) | |
Stage at diagnosis | 0.95 | ||||
1–2 | 19 (17) | 11 (16) | 6 (18) | 2 (14) | |
3–4 | 96 (83) | 56 (84) | 28 (82) | 12 (86) | |
Missing | 4 | 2 | 1 | 1 | |
B symptoms at diagnosis | 0.62 | ||||
No | 81 (74) | 44 (70) | 25 (78) | 12 (80) | |
Yes | 29 (26) | 19 (30) | 7 (22) | 3 (20) | |
Missing | 9 | 6 | 3 | 0 | |
LDH higher than institutional baseline | 0.80 | ||||
No | 70 (71) | 43 (71) | 20 (74) | 7 (64) | |
Yes | 29 (29) | 18 (29) | 7 (26) | 4 (36) | |
Missing | 20 | 8 | 8 | 4 | |
Albumin at diagnosis | 0.75 | ||||
Normal | 80 (81) | 49 (80) | 22 | 9 | |
Low | 19 (19) | 12 (20) | 4 | 3 | |
Missing | 20 | 8 | 9 | 3 | |
Monoclonal protein at diagnosis | 0.05 | ||||
No | 49 (56) | 30 (54) | 17 (74) | 2 (25) | |
Yes | 38 (44) | 26 (46) | 6 (26) | 6 (75) | |
Missing | 32 | 13 | 12 | 7 | |
BM involvement at diagnosis | 0.72 | ||||
No | 32 (32) | 17 (30) | 10 (33) | 5 (42) | |
Yes | 67 (68) | 40 (70) | 20 (67) | 7 (58) | |
Not done | 20 | 11 | 5 | 3 | |
TP53 mutation/17p deletion (n = 67)* | 0.99 | ||||
No | 19 (28) | 10 (23) | 7 (47) | 2 (25) | |
Yes | 10 (15) | 7 (16) | 2 (13) | 1 (13) | |
Unavailable/not tested | 38 (57) | 27 (61) | 6 (40) | 5 (62) | |
Complex cytogenetics (n = 67)* | 0.16 | ||||
No | 57 (85) | 37 (90) | 17 (85) | 6 (67) | |
Yes | 10 (15) | 4 (10) | 3 (15) | 3 (33) | |
Primary refractory disease** | 0.07 | ||||
No | 89 (75) | 56 (81) | 25 (71) | 8 (53) | |
Yes | 30 (25) | 13 (19) | 10 (29) | 7 (47) | |
First-line therapy | 0.47 | ||||
Rituximab | 58 (49) | 35 (51) | 19 (54) | 4 (27) | |
BR | 30 (25) | 16 (23) | 9 (26) | 5 (33) | |
R-CVP | 11 (9) | 7 (10) | 1 (3) | 3 (20) | |
R-CHOP | 9 (8) | 5 (7) | 2 (6) | 2 (13) | |
Others | 11 (9) | 6 (9) | 4 (11) | 1 (7) | |
Receipt of maintenance R | 0.27 | ||||
No | 88 (74) | 47 (68) | 29 (83) | 12 (80) | |
Yes | 31 (26) | 22 (32) | 6 (17) | 3 (20) | |
Line of ibrutinib therapy | 0.40 | ||||
Second line | 54 (45) | 31 (45) | 16 (46) | 7 (47) | |
Third line | 41 (35) | 27 (39) | 9 (26) | 5 (33) | |
Fourth line and beyond | 24 (20) | 11 (16) | 10 (28) | 3 (20) | |
Median f/up in months (range)^ | 23 (1–75) | 23 (1–72) | 26 (3–75) | 6 (3–22) |